SNCE SCIENCE 37 HLDGS INC

Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”

Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”

Science 37’s Patient Recruitment Recognized in Prestigious International Annual Awards Program for Standout Digital Health & Medical Technology Products and Companies

RESEARCH TRIANGLE PARK, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- , today announced its selection as winner of the “Clinical Efficiency Innovation Award” in the 8th annual MedTech Breakthrough Awards program.

, an independent market intelligence organization, recognized Science 37 for its transformative solution to clinical research patient recruitment. By leveraging its nationwide medical licensure and AI-powered patient screening capabilities, Science 37’s Patient Recruitment solution engages, medically qualifies, and delivers fully consented participants to sites prior to their first study visit. This unique approach creates a better patient experience, increases patient randomization rates, improves site satisfaction, and nearly eliminates patients being redirected to competing studies.

“We understand the difficulty in turning referrals into consented participants and have worked hard to address these issues by revolutionizing the conventional approaches head-on,” said Erica Prowisor, SVP Patient and Site Networks at Science 37. “This award from MedTech Breakthrough highlights our work to mitigate the core challenges of conventional recruitment methods resulting in a win-win for sponsors and sites. We’ll continue to transform patient recruitment by delivering an improved process designed to increase enrollment and site/primary investigator productivity.”

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records (EHR), Virtual Care, Medical Devices, Medical Data & Privacy, and many more. This year’s program attracted thousands of nominations from over 18 different countries throughout the world.

“The ability to find, recruit, and enroll participants is a huge challenge for clinical trials, resulting in 80% of them being delayed, and the majority of participant referrals are not even fully qualified,” said Steve Johansson, Managing Director at MedTech Breakthrough. “By delivering fully consented and medically qualified participants directly to sites, sponsors, and CROs, Science 37 eliminates common issues of disengaged site staff and having referrals diverted to competing studies. Science 37's Patient Recruitment is more than a solution—it's a leap forward in clinical trial efficiency and innovation—and we’re thrilled to recognize the entire Science 37 team for taking home our ‘Clinical Efficiency Innovation Award’ in 2024.”

About MedTech Breakthrough



Part of , a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical & health technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include Patient Experience & Engagement, Health & Fitness, Medical Devices, Clinical Administration, Connected Healthcare, Medical Data, Healthcare Cybersecurity and more. For more information visit . 

Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.

About Science 37

Science 37’s mission is to accelerate clinical research by enabling universal trial access for patients. Through our solutions; the Metasite™ and Patient Recruitment, we accelerate enrollment by expanding the reach of clinical trials to patients beyond the traditional site and rigorously qualifying patients prior to referring them to a traditional site. Our solutions are powered by a proprietary technology stack with in-house medical and operational experts that enhance quality through standardized workflows and best-in-class study orchestration. To learn more, visit , or email .

To view studies that Science 37 is actively recruiting for, please visit .

Media Inquiries



Science 37

 



EN
09/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SCIENCE 37 HLDGS INC

 PRESS RELEASE

Science 37 Completes Third FDA Inspection, Validating Quality of its D...

Science 37 Completes Third FDA Inspection, Validating Quality of its Direct-to-Patient Site in Pivotal Phase 3 Rare Disease Trial MORRISVILLE, N.C., Oct. 08, 2025 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, today announced the successful completion of its third FDA inspection, further affirming the quality and compliance of its Direct-to-Patient Site for clinical research. The inspection concluded with a No Action Indicated (NAI) categorization recommendation by the inspector, with no objectionable conditions noted and no Form 483 issued. The review cen...

 PRESS RELEASE

Science 37 and Catalent Announce Partnership Enabling Universal Access...

Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research MORRISVILLE, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- , the leader in expanding patient access to clinical trials, and ®, a global leader in enabling pharma, biotech, and consumer health partners to optimize product development and supply, announced a strategic partnership redefining how investigational medicinal products (IMPs) are delivered directly to patients’ homes for clinical research. Through this collaboration, Catalent supports Science 37’s Direct-to-Patient Clinical Trial Site model by ...

 PRESS RELEASE

Science 37 Completes Second FDA Inspection as Enrollment Leader in Pha...

Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial MORRISVILLE, N.C., April 08, 2025 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, today announced the successful completion of its second FDA inspection, reaffirming the quality of its Direct-to-Patient Site for clinical research. The inspection resulted in a No Action Indicated (NAI) categorization, with no objectionable conditions noted and no Form 483 issued. Led by Science 37's internal Quality Assurance & Compliance team, the inspection focused on the company’s role...

 PRESS RELEASE

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-...

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation Seasoned Strategist and Former Chief Commercial Officer Poised to Accelerate Access and Equity in Clinical Research MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer. Formerly the company’s Chief Commercial Officer, Van Horn’s appointment follows his pivotal role in driving operational excellence and shaping the company’s strategic direction to better prioritize client ...

 PRESS RELEASE

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease...

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial MORRISVILLE, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a Phase 3 rare disease trial sponsored by global biopharmaceutical company, . The hepatology study of an investigational medicine for cholestatic pruritus in primary biliary cholangitis (PBC) required 230 global participants, of which Science 37 was able to contribute almost half (17 - 47%) of the U.S. enrollment for the study. Recognizing that t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch